Pfizer Stock News

Pfizer stock slipped a fraction early Tuesday, but the company raised its guidance for the year and named a new CFO.

Stock-market futures are mixed this morning, with the Dow pointing to a lower open after finishing yesterday the only leading index to manage a gain; voters are preparing for Election Day in the U.S.; shares of Apple and Palantir are falling after reporting their latest financial results last night; and investors are watching for more updates from big companies today, including from AMD.

Pfizer boosted its guidance for the year, citing momentum in newly-launched and acquired products that helped offset declining sales for its Covid-19 vaccine and treatments.

Pfizer boosts full-year guidance on the back of its latest quarter, citing growth in non-Covid offerings and acquired products.

Pfizer reported third-quarter results that topped estimates and hiked its full-year outlook, citing its "strong year-to-date performance" and ongoing cost cuts.  Pfizer also announced that Cecile Guegan, who has held various finance leadership roles at the company over the last two decades, stepped in as chief financial officer this month.

Pfizer raised its annual forecasts on Tuesday as strong demand for its cancer drugs ​and blockbuster blood thinner Eliquis helped the drugmaker post better-than-expected third-quarter ‌results.

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2026 and raised its full-year 2026 guidance(2) for both Revenues and Adjusted(3) diluted EPS. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing our strategy for creating long...